Applied Filters
Galderma sues Lupin over Oracea generic
Galderma Laboratories has sued Lupin Pharmaceuticals alleging that it plans to manufacture and sell a generic version of Oracea prior to the expiration of key patents.
Fed Circuit split decision denies Biogen’s bid to revive MS drug patent
The US Court of Appeals for the Federal Circuit has refused Biogen’s attempt to revive a key patent for its multiple sclerosis drug Tecfidera (dimethyl fumarate), leaving Mylan’s successful challenge intact.
Court denies Sun Pharma’s bid to avoid trial
Sun Pharma’s bid to avoid facing a trial over allegations of antitrust behaviour by an Indian drugmaker it acquired has been denied by a Massachusetts court.
Bayer, Onyx drop Nexavar patent suit
Bayer Healthcare and Amgen subsidiary Onyx Pharmaceuticals have dropped a patent infringement suit against Dr Reddy’s over a planned generic version of cancer treatment Nexavar.
PTAB grants IPR of Regeneron Eylea patents
The US Patent Trial and Appeal Board will review the validity of two Regeneron Pharmaceuticals patents related to its Eylea (aflibercept) medication.
EPO upholds Bayer's Xarelto dosage patents
Following two-day oral proceedings at the Munich Board of Appeal of the European Patent Office, the court has upheld the validity of a Bayer Pharmaceuticals’ dosing patent for Xarelto.
Pfizer fights approval of generic Ibrance
Pfizer is seeking to block a generic version of its cancer drug Ibrance from entering the market until the patent covering the drug expires in May 2036.
Azurity sues Bionpharma over newly issued patent
Azurity Pharmaceuticals has sued Massachusetts drug company Bionpharma, claiming that its generic of Azurity’s Epaned product infringes on a brand new patent.
AstraZeneca wins patent infringement case over Farxiga generic
AstraZeneca has convinced a federal court to uphold challenged claims of a patent related to its diabetes drug Farxiga.
Jazz Pharma accused of pay-for-delay deals over Xyrem
Molina Healthcare claims that Jazz Pharmaceuticals delayed generics of its flagship narcolepsy drug Xyrem and hiked the drug prices to increase profits when it was on the verge of bankruptcy.
